Dublin, Feb. 03, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Transdermal Drug Delivery - Technologies, Markets, and Companies" to their offering.
This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral,intravascular, subcutaneous and transmucosal routes.
Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers. The most commonly used transdermal system is the skin patch using various types of technologies. Nanoparticles as well as the use of physical agents to facilitate transcutaneous drug delivery is described. Microneedle and needleless technologies are also described.
Transdermal technologies may be applied for several categories of pharmaceuticals used for the treatment of disorders of the skin or for systemic effect to treat diseases of other organs. Several transdermal products and applications include hormone replacement therapy, contraception, management of pain, angina pectoris, smoking cessation and neurological disorders such as Parkinson's disease.
The market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2016 to 2026. This market is analyzed according to geographical regions as well.
Benefits of this report
- Up-to-date one-stop information on transdermal drug delivery
- Description of 110 companies involved and 110 collaborations in this area
- Market analysis 2016-2026
- Market values in major regions
- Strategies for developing markets for transdermal drug delivery
- A selected bibliography of 220 publications
- Text is supplemented by 22 tables and 14 figures
Key Topics Covered:
Executive Summary
1. Basics of Transdermal Drug Delivery
2. Transdermal Drug Delivery Technologies
3. Transdermal Therapeutics
4. Markets for Transdermal Drug Delivery
5. Companies involved in transdermal drug delivery
6. References
For more information about this report visit http://www.researchandmarkets.com/research/ckhpvw/transdermal_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Transdermal and Transmucosal Drug Delivery


LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 



